ISTH/LinkedIn
May 19, 2026, 15:57
Explore the Emerging Science Behind Factor XI/XIa Inhibition on the ISTH Academy – ISTH
International Society on Thrombosis and Haemostasis (ISTH) shared a post on LinkedIn:
“What if stroke prevention didn’t have to come with the same level of bleeding risk?
Explore the emerging science behind factor XI/XIa inhibition in this new learning resource on the ISTH Academy.
Review the role of FXI in thrombosis and hemostasis, examine key clinical trial data and discover how these therapies may reshape secondary stroke prevention.
- Includes real-world clinical scenarios
- CME credit available upon completion
Start learning today with the ISTH Academy.”
Other posts featuring International Society on Thrombosis and Haemostasis on Hemostasis Today.
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation
-
Aug 21, 2026, 09:07Sujal Lohana: Building a Better Blood Donor–Seeker App
-
Aug 21, 2026, 08:55Robert Sidonio: Connecting Experts in Bleeding and Clotting Disorders